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Abstract
ANCA vasculitis has an associated autoimmune response that produces ANCAs that induce distinct pathologic
lesions.Pauci-immunenecrotizingandcrescenticGNis a frequentcomponentofANCAvasculitis.ANCAvasculitis
is associated with ANCA specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). A diagnosis of
ANCA vasculitis should always specify the serotype as MPO-ANCA positive, PR3-ANCA positive, or ANCA-
negative. To fully characterize a patient, the serotype also should be accompanied by the clinicopathologic variant
if this can be determined: microscopic polyangiitis, granulomatosis with polyangiitis (Wegener), eosinophilic
granulomatosis with polyangiitis (Churg–Strauss), or renal-limited vasculitis. ANCA vasculitis is most prevalent in
individuals >50 years old. There are racial/ethnic and geographic influences on the prevalence, serotype
frequencies, and clinicopathologic phenotypes. There is clinical, in vitro, and animal model evidence that ANCAs
cause disease by activating neutrophils to attack small vessels. Immunomodulatory and immunosuppressive
therapies are used to induce remission, maintain remission, and treat relapses. Over recent years, there have been
major advances in optimizing treatment by minimizing toxic therapy and utilizing more targeted therapy.
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Introduction
GN and vasculitis caused by ANCAs is the most com-
mon form of new-onset GN in adults .50, although
it can occur at any age. Prompt diagnosis and initi-
ation of appropriate immunosuppressive therapy is
essential for optimum patient and renal outcomes.
Diagnosis and treatment of ANCA disease is compli-
cated by the marked differences in symptoms, signs,
activity, chronicity, and severity among patients. This
review will summarize the spectrum of clinicopath-
ologic phenotypes and serotypes of ANCA disease,
the related epidemiologic and demographic charac-
teristics, the underlying pathogenic mechanisms, and
the current approaches to treatment.
Diagnostic Classification
ANCA GN and vasculitis are defined by distinct
pathologic lesions and an associated autoimmune re-
sponse that produces ANCAs. The 2012 Chapel Hill
Consensus Conference Nomenclature of Vasculitides
(CHCC 2012) defines ANCA-associated vasculitis
as necrotizing vasculitis, with few or no immune de-
posits, predominantly affecting small vessels (i.e.,
capillaries, venules, arterioles, and small arteries)
(Table 1) (1). ANCA vasculitis is associated with
ANCA specific for myeloperoxidase (MPO-ANCA)
or proteinase 3 (PR3-ANCA). On the basis of path-
ologic and clinical features, ANCA-associated vas-
culitis is subdivided into microscopic polyangiitis
(MPA), granulomatosis with polyangiitis (Wegener)
(GPA), and eosinophilic granulomatosis with poly-
angiitis (Churg–Strauss) (EGPA) (Table 1), as well as
renal-limited vasculitis (RLV) with pauci-immune
necrotizing GN alone with no evidence for systemic
vasculitis (1). Unlike MPA, GPA has extravascular
granulomatous inflammation, most often in the re-
spiratory tract. EGPA has extravascular granuloma-
tous inflammation as well as blood eosinophilia and
asthma. Less than 10% of patients with clinical and
pathologic features of MPA, GPA, RLV, and EGPA
with necrotizing GN are negative for ANCA using
current clinical assays. To be most helpful for clinical
management, an ANCA disease diagnosis in a given
patient should include both the serotype and the
clinicopathologic phenotype, if known. For example,
CHCC 2012 calls for adding a prefix to the clinico-
pathologic phenotype indicating the ANCA specificity
in a given patient with ANCA-associated vasculitis (i.e.,
MPO-ANCAGPA, PR3-ANCAMPA, ANCA-negative
MPA, etc.) (1).
Clinicopathologic Classification
Pauci-immune necrotizing and crescentic GN is the
typical pattern of glomerular injury in all forms of
systemic ANCA-associated vasculitis (2). ANCA-
associated pauci-immune necrotizing and crescentic
GN also occurs in the absence of systemic vasculitis as
so-called RLV. The characteristic acute lesion in
glomeruli as well as other vessels in the kidney and
throughout the body is localized vessel wall necrosis,
which releases constituents of the plasma, includ-
ing coagulation factors, into the necrotic zone where
thrombogenic factors, such as tissue factor, activate
the coagulation cascade to produce fibrin. This ne-
crotic area filled with fibrin is called fibrinoid necrosis
(Figure 1). Unlike immune complex GN and anti–
glomerular basement membrane (anti-GBM) crescentic
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GN that have extensive localization of immunoglobulin in
glomeruli detected by immunofluorescence microscopy,
ANCA GN has a paucity of staining for immunoglobulin
in glomeruli (2).
The pathologic activity and chronicity of ANCA GN can
be classified by Berden et al. (3) on the basis of the extent of
glomerular crescents and sclerosis, and the proportion of
glomeruli with no lesion by light microscopy. Focal class
with $50% normal glomeruli has the least progression to
ESRD, sclerotic class with $50% globally sclerotic glo-
meruli has the worst progression, and crescentic class
with $50% glomerular crescents and mixed class with no
predominance of a lesion type have intermediate pro-
gression (3). A caveat is that in patients with eGFR,15
ml/min per 1.73 m2, the Berden class does not predict
renal outcome (4). In this setting, normal glomeruli #10%
(P50.04) and higher overall chronicity score (P50.02) are
risk factors for ESRD.
Serologic Classification
Serologic classification of ANCA-associated vasculitis
(e.g., MPO-ANCA, PR3-ANCA, ANCA-negative) as well as
clinicopathologic classification (e.g., MPA, GPA, EGPA,
RLV), and combinations of both, are useful for character-
izing the nature and outcome of the disease in a given
patient, and for predicting the prognosis and response to
treatment (5,6). When used in patient management, ANCA
testing should be performed by a clinical laboratory that
can determine ANCA specificity for PR3 and MPO (7).
Accurate assays for ANCA are valuable for diagnosis and
prognostication (8); however, ANCA titers are more pre-
dictive of renal disease activity than nonrenal disease
activity (9). Patients with ANCA GN who become ANCA
negative during follow-up have low risk for relapse, and a
rise in ANCA titer increases the likelihood of relapse .11
times (9).
Classifying patients on the basis of PR3-ANCA versus
MPO-ANCA correlates with a number of disease charac-
teristics (10). PR3-ANCA vasculitis is more common in
northern Europe, northern North America, and Australia;
whereas MPO-ANCA vasculitis is more common in south-
ern Europe, southern United States, and Asia. PR3-ANCA
has an HLA-DP genetic association whereas MPO-ANCA
vasculitis has an HLA-DQ association. PR3-ANCA vascu-
litis has more upper respiratory tract disease whereas
MPO-ANCA vasculitis has more renal disease. PR3-ANCA
vasculitis has more granulomatous inflammation andMPO-
ANCA vasculitis less granulomatous inflammation. At the
time of biopsy, PR3-ANCA GN has more necrosis and
MPO-ANCA GN has more sclerosis.
Our data from the University of North Carolina (UNC)
indicate that ANCA specificity independently predicts
relapse among patients with ANCA vasculitis more effec-
tively than classification systems that use only the clinico-
pathologic phenotype, with PR3-ANCA–positive patients
Table 1. CHCC 2012 categories of ANCA-associated vasculitis (modified from reference (1))
CHCC 2012 Name CHCC 2012 Definition
ANCA-associated vasculitis Necrotizingvasculitis,with feworno immunedeposits,predominantlyaffecting
smallvessels (i.e., capillaries, venules, arterioles, andsmall arteries), associated
with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA. Not all
patients have ANCA. Add a prefix indicating ANCA reactivity, e.g., MPO-
ANCA, PR3-ANCA, ANCA-negative.
Microscopic polyangiitis Necrotizingvasculitis,with feworno immunedeposits,predominantlyaffecting
small vessels (i.e., capillaries, venules, or arterioles). Necrotizing arteritis
involving small andmedium arteries may be present. Necrotizing GN is very
common.Pulmonarycapillaritis oftenoccurs.Granulomatous inflammation is
absent.
Granulomatosiswith polyangiitis
(Wegener)
Necrotizing granulomatous inflammation usually involving the upper and
lower respiratory tract, and necrotizing vasculitis affecting predominantly
small-to-medium vessels (e.g., capillaries, venules, arterioles, arteries, and
veins). Necrotizing GN is common.
Eosinophilic granulomatosiswith
polyangiitis (Churg–Strauss)
Eosinophil-rich and necrotizing granulomatous inflammation often involving
the respiratory tract, andnecrotizingvasculitis predominantly affecting small-
to-medium vessels, and associated with asthma and eosinophilia. ANCA is
more frequent when GN is present.
CHCC 2012, 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides.
Figure 1. | Photomicrographs of a kidney biopsy specimen from a
patient with ANCA vasculitis showing segmental fibrinoid necrosis.
In a glomerulus (A) and an interlobular artery (B) (short arrows). The
glomerulus has a small cellular crescent (long arrow), and a break in
Bowman’s capsule in the upper left corner. (Masson trichrome stain.)
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approximately twice as likely to relapse compared with
MPO-ANCA–positive patients (hazard ratio, 1.89; 95%
confidence interval, 1.33 to 2.69; P,0.001) (5). ANCA spec-
ificity has the best predictive model fit compared with
classification on the basis of the CHCC 2012 definitions
(1), or the European Medicines Agency classification (11).
Tables 2 and 3 show demographic and selected clinical
data from an inception cohort of ANCA vasculitis patients
primarily from the southeastern United States seen at
UNC between 1985 and 2007 (5). This cohort came from
a nephrology-based clinical setting, and thus is skewed
toward patients encountered by nephrologists. This co-
hort included 502 ANCA-positive patients diagnosed with
biopsy-confirmed ANCA vasculitis (including MPA, GPA,
and RLV, but excluding EGPA) followed by the Glomerular
Disease Collaborative Network. Patients with EGPA are rarely
seen by nephrologists at UNC. Patients received conventional
therapies (5). Figure 2, which shows organ system involve-
ment in this cohort, demonstrates that the MPO-ANCA and
PR3-ANCA serotypes correlate with different predilections for
organ involvement (5). At one extreme are RLV patients with
GN as the only expression of vasculitis, with approximately
80% of patients MPO-ANCA positive. At the other extreme
are patients with destructive lesions in the nasal septum with
.90% positivity for PR3-ANCA. Patients with pulmonary
capillaritis and no nodules or cavities have a similar frequency
of MPO-ANCA and PR3-ANCA, whereas patients with lung
nodules or cavities more often have PR3-ANCA.
Epidemiology, Demographics, and Genetics
MPA, GPA, and EGPA have a peak incidence of 65–75,
but may occur at any age, with a slight male predominance
(12). Figure 3 shows data derived from 21,374 patients
with any form of glomerular disease identified in renal
biopsy specimens evaluated by the University of North
Carolina Nephropathology Laboratory from 1986 to 2015
(13). Only a subset of the most common glomerular disease
categories that cause GN are shown on these graphs. In
patients with GN ,60 years old, lupus nephritis and IgA
nephropathy are diagnosed most often, whereas ANCA GN is
diagnosed most often after 60 years old (13). As a percentage
of all biopsies performed in different age groups (panel on
the right in Figure 3), IgA nephropathy declines with age,
lupus nephritis peaks in early adulthood, and ANCA GN
increases with age, with a dramatic surge after 50 years old.
ANCAvasculitis has geographic and race/ethnic differences
in prevalence (12). In the United Kingdom, GPA is more
prevalent than MPA (148 versus 65 per million), and EGPA is
least prevalent (46 per million). ANCA vasculitis prevalence in
France is higher in people with European lineage compared
with non-European lineage (105 per million versus 53 per
million). In North America, ANCA vasculitis incidence is
greater in whites than in blacks, which may be caused by HLA
differences (14). ANCA vasculitis is less common in blacks,
occurs at a younger age (mean 52 versus 57 years), and is more
oftenMPO-ANCA positive compared with whites (71% versus
54%) (15). There are no differences compared with whites in
treatment response, ESRD, renal relapse, or death.
In the United Kingdom and northern Europe, PR3-ANCA
and GPA are more common than MPO-ANCA; however, in
southern Europe, Asia, and India, MPO ANCA and MPA are
more common than PR3-ANCA and GPA (12). In the United
States, there is a similar trend with more PR3-ANCA and
GPA in northern states and more MPO-ANCA-and MPA in
southern states. In China, GPA patients more often have MPO-
ANCA than PR3-ANCA. Geographic and racial differences in
serotypes and clinicopathologic phenotypes may be deter-
mined by HLA differences (14,16,17).
Although only approximately 50% of patients with EGPA
have ANCA, which is usually MPO-ANCA, the presence
of ANCA correlates with phenotypic features of vasculitis
including GN, alveolar capillaritis, and peripheral neu-
ropathy (12). The GN in MPA, GPA, EGPA, and RLV is
histologically indistinguishable (2).
Table 2. Patient characteristics on the basis of clinicopathologic phenotype (RLV, MPA, GPA) of an inception cohort of patients with
ANCA vasculitis with high-frequency renal involvement evaluated at the University of North Carolina Kidney Center (excluding patients
with eosinophilic granulomatosis with polyangiitis). The proportion of patients with each characteristic (other than age) is expressed as a
percent of RLV patients, MPA patients and GPA patients.
Characteristic RLV n5121 MPA n5264 GPA n5117
P Valuea RLV
versus MPA
versus GPA
P Valuea
RLV versus
MPA/GPA
P Valuea
MPA versus
GPA
Diagnosis age ,0.001 ,0.01 ,0.001
Mean6SD 59.8618.4 57.5618.1 47.9619.8
Median (IQR) 66 (50, 73) 61 (49, 71) 50 (32, 64)
MPO/PR3 ,0.001 ,0.001 ,0.001
MPO 98 (81.0%) 155 (58.7%) 30 (25.6%)
PR3 23 (19.0%) 109 (41.3%) 87 (74.4%)
Kidney involvement 121 (100%) 262 (99.2%) 105 (89.7%) ,0.001 ,0.03 ,0.001
Lung involvement 0 (0%) 157 (59.5%) 95 (81.2%) ,0.001 NA ,0.001
ENT involvement 0 (0%) 97 (36.7%) 88 (75.2%) ,0.001 NA ,0.001
Theproportionofpatientswitheachcharacteristic (other thanage) isexpressedasapercentofRLVpatients,MPApatientsandGPApatients.
Other characteristics of this cohortwerepublishedbyLionaki et al. (5). (MPA/GPA5all patientswithMPAandwithGPAcombined.)RLV,
renal-limitedvasculitis;MPA,microscopic polyangiitis;GPA, granulomatosiswith polyangiitis; IQR, interquartile range; PR3,proteinase 3;
NA, not aplicable becuase by definition RLV patients do not have lung or ENT involvement.; ENT, ear, nose and throat.
aP values are calculated using Fisher’s exact test for categoric variables and Wilcoxon two-sample test for continuous variables.
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The demographic data in Tables 2 and 3 are representative
of ANCA-positive patients with ANCA vasculitis in the south-
eastern United States (5). Among these patients, approxi-
mately a quarter have RLV, a quarter have GPA, and half
have MPA. MPO-ANCA occurred in 81% of RLV, 59% of
MPA, and 26% of patients with GPA. Conversely, PR3-ANCA
occurred in 19% of RLV, 41% of MPA, and 74% of patients
with GPA. During the time when this cohort of patients was
identified,,5% of patients at UNC with clinical and pathologic
features of ANCA vasculitis were ANCA-negative. These
patients are not included in Tables 2–4. Patients with concur-
rent ANCA and anti-GBM disease also were not included.
Figure 2. | Frequency of PR3-ANCA andMPO-ANCA positivity in ANCA-positive patients with a particular organ system involvement in an
inception cohort of 502 ANCA vasculitis patients with MPA, GPA, or RLV evaluated at the University of North Carolina Kidney Center
(excluding patients with EGPA) (Modified from Lionaki et al. [5]). Organ groupings are not mutually exclusive. ‘No lung and no ENT’ has
vasculitis in some other organs. Plusmeans there is vasculitis in an additional organ. EGPA, eosinophilic granulomatosiswith polyangiitis; ENT,
ear, nose and throat; GI, gastrointestinal tract; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO-ANCA, ANCA
specific for myeloperoxidase; PR3-ANCA, PR3-ANCA, ANCA specific for proteinase 3; RLV, renal-limited vasculitis.
Table 3. Patient characteristics on the basis of ANCA specificity (MPO-ANCA, PR3-ANCA) of an inception cohort of patients with
ANCA vasculitis with high-frequency renal involvement evaluated at the University of North Carolina Kidney Center (excluding patients
with eosinophilic granulomatosis with polyangiitis). The proportion of patients with each characteristic (other than age) is expressed as a
percent of all ANCA disease patients, MPO-ANCA disease patients and PR3-ANCA disease patients.
Characteristic All n5502 MPO-ANCA n5283 PR3-ANCA n5219 Pa Value MPO versus PR3
Age at diagnosis ,0.001
Mean6SD 55.8619.1 59.2617.6 51.5620.0
Median (IQR) 60 (46, 71) 64 (50, 72) 56 (38, 67)
CHCC ,0.001
RLV 121 (24.1%) 98 (34.6%) 23 (10.5%)
MPA 264 (52.6%) 155 (54.8%) 109 (49.8%)
GPA 117 (23.3%) 30 (10.6%) 87 (39.7%)
Kidney involvement 488 (97%) 282 (99.7%) 206 (94.1%) 0.001
Lung involvement 252 (50%) 117 (41.3%) 135 (61.6%) ,0.001
ENT involvement 185 (37%) 67 (23.7%) 118 (53.9%) ,0.001
The proportion of patientswith each characteristic (other than age) is expressed as a percent of all ANCAdisease patients,MPO-ANCA
disease patients and PR3-ANCA disease patients. Other characteristics of this cohort were published by Lionaki et al. (5). MPO-ANCA,
ANCAspecificformyeloperoxidase;PR3-ANCA,ANCAspecific forproteinase3;MPO,myeloperoxidase;PR3,proteinase3; IQR, interquartile
range;CHCC,2012ChapelHillConsensusConferenceVasculitisNomenclature;RLV, renal-limitedvasculitis;MPA,microscopicpolyangiitis;
GPA, granulomatosis with polyangiitis; ENT, ear nose and throat.
aP values are calculated using Fisher’s exact test for categoric variables and Wilcoxon two-sample test for continuous variables.
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Approximately 5% of patients with ANCA vasculitis also
have anti-GBM antibodies, and approximately 35% of patients
with anti-GBM disease have ANCA (usually MPO-ANCA)
(18). These patients have kidney disease that more closely
resembles anti-GBM disease, i.e., it is more severe patholog-
ically and clinically, and the risk of progression to ESRD is
greater than for ANCA GN in the absence of anti-GBM.
Table 4 demonstrates responses to treatment of a large
ANCA vasculitis cohort managed by nephrologists in the
southeastern United States from 1985 to 2007 (5). The out-
come data represent blended results derived from different
conventional treatment approaches among different ne-
phrologists over several decades. Nevertheless, we believe
that these data provide an informative overview of the
spectrum of patients with ANCA vasculitis encountered
by nephrologists. Note that classification by both ANCA
serotype and clinicopathologic phenotype have statisti-
cally significant correlations with demographic and clinical
Figure 3. | These data are derived from 21,374 patients with any form of glomerular disease identified in renal biopsy specimens evaluated by the
University of North CarolinaNephropathology Laboratory from 1986 to 2015.Only a subset of themost common glomerular disease categories that
cause GN are shown on these graphs (modified from reference 13, with permission). Anti-GBM GN, anti–glomerular basement membrane GN.
Table 4. Outcomes for patients with ANCA vasculitis on the basis of different classification systems evaluated in the same cohort
characterized in Tables 2 and 3
Classification System Treatment Resistance(n5109 of 483)
Relapse
(n5147 of 374)
ESRD
(n5161 of 502)
Death
(n5139 of 502)
Classification on the basis of CHCC 2012 definitions
GPA (n5117) 20 of 117 (17%) 58 of 97 (60%) 24 of 117 (21%) 20 of 117 (17%)
MPA (n5264) 56 of 255 (22%) 74 of 199 (37%) 80 of 264 (30%) 79 of 264 (30%)
RLV (n5121) 33 of 111 (30%) 15 of 78 (19%) 57 of 121 (47%) 40 of 121 (33%)
P value 0.07 ,0.001 ,0.001 ,0.01
European Medicines Agency classification
GPA (n5324) 68 of 317 (22%) 110 of 249 (44%) 92 of 324 (28%) 84 of 324 (26%)
MPA (n5178) 41 of 166 (25%) 37 of 125 (30%) 69 of 178 (39%) 55 of 178 (31%)
P value 0.42 ,0.01 ,0.02 0.25
Classification on the basis of ANCA specificity
PR3-ANCA (n5219) 37 of 213 (17%) 90 of 176 (51%) 56 of 219 (26%) 50 of 219 (23%)
MPO-ANCA (n5283) 72 of 270 (27%) 57 of 198 (29%) 105 of 283 (37%) 89 of 283 (31%)
P value ,0.02 ,0.001 ,0.01 0.03
(ModifiedfromLionaki, etal. [5]).Treatmentresistance5persistenceornewappearanceofextrarenalmanifestationsand/orprogressivedecline
in renal functionwithactiveurine sediment inspiteof immunosuppressive therapy.Relapse5 reactivationofvasculitis inanyorganafter initial
response to treatment. ESRD5 chronic need for dialysis or transplantation. Death5 death from any cause. CHCC 2012, 2012 International
ChapelHillConsensusConferenceontheNomenclatureofVasculitides;GPA,granulomatosiswithpolyangiitis;MPA,microscopicpolyangiitis;
RLV, renal-limited vasculitis; PR3-ANCA, ANCA specific for proteinase 3; MPO-ANCA, ANCA specific for myeloperoxidase.
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parameters (Tables 2–4). For example, in this cohort, 81%
of patients with RLV have MPO-ANCA compared with
59% of patients with MPA and 26% of patients with GPA
(Table 2). From another perspective, 35% of patients with
MPO-ANCA have RLV compared with 10% of patients
with PR3-ANCA (Table 3). Table 4 shows that both
serotype and phenotype correlate with outcomes. For
example, relapse rates are 19% for RLV, 37% for MPA, and
60% for GPA using CHCC 2012 definitions; and 51%
for patients with PR3-ANCA and 29% for patients with
MPO-ANCA.
Pathogenesis
Clinical Support
There is clinical, animal model, and in vitro experi-
mental evidence that ANCAs are pathogenic (19). The
presence of ANCAs in .90% of patients with MPA, GPA,
and RLV raises the possibility that ANCAs are causing
the disease. The efficacy of immunosuppressive and
immunomodulatory therapy in ANCA vasculitis, and
the rough correlation of ANCA titers with response to
therapy and relapse, also support an immune pathogen-
esis. The utility of plasmapheresis and targeted B cell
therapy (e.g., rituximab) suggests a primary pathogenic
role for autoantibodies.
ANCA pathogenicity also is supported by the obser-
vation in one neonate that transplacental transfer of
maternal MPO-ANCA to the child was associated with
development of nephritis and pulmonary hemorrhage
(20). Some drugs, such as hydralazine, propylthiouracil,
penicillamine, and illicit cocaine adulterated with leva-
misole can induce ANCA vasculitis (21). This induction of
ANCAs followed by onset of ANCA vasculitis supports a
causal relationship. However, these associations do not
prove causality, and the presence of an ANCA vasculitis
disease phenotype in patients who are ANCA-negative
by current clinical assays, and the persistence of ANCA
positivity in some patients in remission, raises doubts
about the pathogenic link between ANCAs and ANCA
vasculitis.
One possible explanation for these inconsistent serologic
correlations is that some ANCA epitope specificities are
not pathogenic and thus ANCAs with these specificities
can be present in the absence of active disease, and that
some ANCA are specific for autoantigen epitopes that are
not detected in current serologic assays for ANCA.
Experimental evidence for both possibilities was reported
by Roth et al. (22) who observed that MPO-ANCAs with
certain epitope specificities only occur in patients with
active disease, whereas other MPO-ANCA epitope spec-
ificities occur not only in patients with active disease, but
also in patients in remission and even in very low titers in
healthy controls as natural autoantibodies. Roth et al. (22)
also observed that an MPO epitope recognized by some
pathogenic MPO-ANCAs could not be detected in usual
serologic assays but only in assays that eliminated a serum
blocking factor by using isolated IgG.
In Vitro Evidence
The most compelling evidence for induction of ANCA
vasculitis by ANCAs comes from in vitro and in vivo
experiments (19,23). Figure 4 depicts a putative sequence
of pathogenic events that is consistent with in vitro and in
vivo animal model experiments, and supported by clinical
observations. Each localized vascular lesion resulting from
this process progresses from an acute to a chronic phase
within 1 or 2 weeks; however, multiple new acute lesions
in multiple vessels continue to develop until patients enter
remission. Thus, patients with active disease have accrued
chronic lesions as well as newly developing acute lesions.
This is observed in most ANCA GN renal biopsy speci-
mens as varying numbers of glomeruli with acute necro-
tizing lesions (usually accompanied by crescents), sclerotic
lesions, or both (2).
BothMPO-ANCAand PR3-ANCA IgG can activate primed
normal human neutrophils in vitro causing respiratory
burst with release of toxic oxygen radicals, degranulation
with release of lytic and proinflammatory enzymes, re-
lease of complement alternative pathway–activating fac-
tors, and release of neutrophil extracellular traps (NETS),
which contain extruded DNA with adherent cytoplasmic
proteins that can cause tissue injury and augment the
autoimmune response (19,23,24). Priming of neutrophils,
for example by cytokines, is required for optimum acti-
vation by ANCA IgG. Priming causes a minor degree to
ANCA autoantigens translocation from the cytoplasm to
the cell surface where the autoantigens can interact with
ANCAs. In in vitro and in vivo animal models, tumor ne-
crosis factor suffices as a priming factor. In patients, neu-
trophil priming for activation by circulating ANCA could
be caused by a concurrent synergistic infection, for example a
respiratory tract viral infection. Priming causes neutrophils to
increase the availability of ANCA antigens on their surfaces,
where they are accessible to interact with ANCAs. Neutro-
phils are activated when ANCA IgG bound to ANCA
antigens engages Fc g receptors on the surface of neutro-
phils. ANCA-activated neutrophils adhere to endothelial
cells and release mediators of inflammation and cell injury,
including NETS (19,24) (Figure 4).
Animal Model Evidence
Multiple animal models have been used to demonstrate
the pathogenicity of MPO-ANCAs and also to incriminate
a role for T cells (23,25–27). Interestingly, no convincing
animal model of ANCA vasculitis caused by PR3-ANCA
has been developed. This is probably because of the dif-
ference in the biology of PR3, including the amount pro-
duced, between humans and the experimental animals that
have been used to attempt to cause disease with anti-PR3
antibodies (28).
One animal model that has been reproduced in multiple
labs was first reported by Xiao et al. (25) and entails injection
of mouse anti-MPO antibodies into susceptible strains of
mice resulting, within one week, in pauci-immune necro-
tizing and crescentic GN, and small vessel vasculitis in
other organs. In this model, there is no difference in disease
induction in wild-type mice compared with mice with no
functioning T cells (25). Thus, T cells are not required to
induce acute necrotizing vascular injury. Of course, T cells
are undoubtedly critically important in initiating and
regulating the autoimmune ANCA response in patients,
and in the inflammatory response to injury, even if they are
not involved in causing the acute lesions.
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Multiple studies using the mouse model induced by
anti-MPO IgG have shown that disease is mediated by neu-
trophil activation, prevented by neutrophil depletion,
influenced by genetic background, modulated by Fc g re-
ceptor repertoire, and requires inflammatory amplification
by the alternative complement pathway (23) Unexpectedly,
activation of the alternative complement pathway was
found to play an important role in amplifying ANCA-
induced inflammation (29,30). ANCA-activated neutrophils
release factors that activate the alternative complement
pathway, resulting in the generation of C5a that is strongly
chemotactic for neutrophils and primes neutrophils to
facilitate further activation by ANCAs (29,30).
Observations in patients with ANCA disease support a
role for complement in pathogenesis. Gou et al. (31) observed
changes in the levels of complement components, includ-
ing activation fragments, in the circulation of patients with
ANCA vasculitis that substantiate alternative complement
pathway activation in patients with ANCA vasculitis. They
observed that patients with ANCA vasculitis have increased
plasma levels of alternative pathway activation markers
C3a, C5a, soluble C5b-9, and Bb during active disease but
not remission. The plasma level of Bb correlated with
severity of glomerular injury on the basis of percentage of
cellular crescents in renal biopsy specimens and with
Birmingham Vasculitis Activity Scores (31). Clinical trials are
currently underway to evaluate the value of complement
activation blockade in the treatment of ANCA vasculitis.
Careful studies of renal biopsy specimens from patients
with ANCA GN confirm the presence of many of the
Figure 4. | Diagram depicting the pathogenesis of vascular lesions in ANCA vasculitis and GN. The events from left to right occur sequentially at
each site of injury, and are repeatedly initiated atmultiple sites until induction of remission.Neutrophil priming, for exampleby cytokines generated
by a synergistic infection, primes neutrophils and presents ANCA antigens at the surface and in the microenvironment of neutrophils. ANCA-
activated neutrophils adhere to and penetrate vessel walls, and release destructive inflammatory mediators and undergo NETosis. ANCA-activated
neutrophils release factors that activate the alternative complement pathway,which generatesC5a and amplifies the inflammation byattracting and
primingmoreneutrophils.Atsitesofvesselwalldisruption,plasmaspills intothenecroticzoneandcoagulationfactorsareactivated toproducefibrin,
resulting inafibrinoidnecrosis invessels in tissueandcrescents inglomeruli. Leukocytesundergoapoptosis andnecrosisproducing leukocytoclasia.
Within a few days, the acute inflammation and necrosis is replaced by infiltrating macrophages and lymphocytes, and scarring begins as activated
fibroblasts and myofibroblasts lay down collagen. (Shown only at the right side of the acute lesion is monocyte activation by ANCA, which is oc-
curring in parallel with neutrophil activation at all sites of acute injury.) NET, neutrophil extracellular trap.
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mediators incriminated in animal studies, and illustrated
in Figure 4. For example, in one study of MPO-ANCA GN
biopsy specimens, active lesions contained neutrophils,
monocytes, macrophages, T cells, NETS, and cellular and
extracellular MPO, including MPO decorating NETS (32).
Genesis of ANCA Autoimmunity
There is a general understanding of the likely pathogenic
events that cause vascular injury. However, there is less
understanding of the initial cause for the autoimmune res-
ponse that results in ANCA production. Adaptive immune
responses begin with presentation of antigens to the im-
mune system in the antigen-presenting pocket of HLA
molecules, which will present the antigen to the T cell re-
ceptor, which in turn influences the specificity of the B cell
receptor (i.e., the immunoglobulin molecule). This predicts
that different HLA molecules would be involved in initi-
ating the MPO-ANCA autoimmune response versus the
PR3-ANCA autoimmune response. This was in fact ob-
served in patients with ANCA vasculitis by genome-wide
association studies that showed specific, and different, HLA
associations with MPO-ANCA and PR3-ANCA vasculitis
(16,17). Not surprisingly given their lineal role in immune
responses, the HLA associations correlated better with
ANCA specificity than with clinicopathologic phenotypes.
Another genetic influence that may affect the genesis of
an immune response, or the intensity of pathogenic event,
is epigenetically controlled increased expression of ANCA
autoantigens. The MPO and PRTN3 genes in peripheral
blood neutrophils and monocytes, that produce MPO and
PR3, respectively, are overexpressed in patients with ac-
tive ANCA vasculitis compared with patients in remission
and healthy controls, as a result of epigenetic dysregula-
tion (33). Increased expression of MPO and PR3 genes
may influence disease pathogenesis either by augmenting
ANCA-induced neutrophil activation, or stimulating the
pathogenic autoimmune response, or both.
ANCA-induced neutrophil activation causes NETosis.
NETosis is a form of neutrophil activation and cell death
that results in the release of NETS that contain a frame-
work of extruded DNA from decondensed chromatin
decorated with multiple adherent cytoplasmic proteins,
including MPO and PR3, many of which have antimicro-
bial properties. NETosis could contribute to the pathoge-
nies of ANCA disease, both by presenting PR3 and MPO
proteins to the immune system in a way that facilitates
the autoimmune ANCA response, and by mediating in-
flammatory injury at sites of ANCA-induced activation
through destructive enzymes and complement-activating
factors (24).
Another hypothetic mechanism for initiating an ANCA
autoimmune response entails an initial response to com-
plementary (antisense) peptides that induces anti-idiotypic
antibodies that react with sense peptides (autoantigen
epitopes) (34). Both antibodies (34) and T cells (35) specific
for complementary PR3 have been detected in patients with
ANCA vasculitis. Evaluation of the functional significance
of ANCA vasculitis genome-wide association study data
also suggested a role for immune recognition of comple-
mentary peptides by T cells (17).
Although the mechanisms are not fully elucidated,
both the adaptive and innate immune systems clearly are
responsible for causing ANCA vasculitis. Thus, appropri-
ate immunosuppression and immunomodulation therapy
are likely to ameliorate ANCA vasculitis injury.
Treatment
For decades, conventional treatment of ANCA disease
with major organ involvement has been with high-dose
cyclophosphamide and glucocorticoids, which has induced
remission in approximately 75% of patients at 3 months
and up to 90% at 6 months, although relapses and adverse
side effects were frequent. More recently, new treatment
regimens have been developed to limit cyclophosphamide
and glucocorticoid exposure during both the induction and
maintenance phases. Biologic therapies that target specific
cellular and molecular components of the autoimmune
response and the mediators of inflammatory injury may be
more effective and less toxic.
Timely diagnosis and institution of appropriate immu-
nomodulatory therapy is critically important for optimum
renal outcome in patients with ANCA GN; however, pa-
tients often have delay in diagnosis and treatment because
of delay in referral to a nephrologist by a primary care
physician, and by patients not going to physicians at the
onset of symptoms. In a study of 127 patients with ANCA
GN by Poulton et al. (36), 71% had a delay in primary care
physician referral to a nephrologist, and 57% of patients
who delayed seeking care had a delay in diagnosis and
appropriate treatment. Patients with initial flu-like or upper
respiratory tract symptoms were more likely to have a delay
in diagnosis, perhaps because these symptoms suggested
common nonprogressive infections to the patient and the
primary care physician.
Induction of Remission
The most widely used current induction therapy com-
prises cyclophosphamide combined with glucocorticoids
(Figure 5). The optimum dose, duration, and route of admin-
istration of cyclophosphamide and rituximab therapy have
been studied inmultiple clinical trials (e.g., 37–40). There is no
randomized trial to guide dosage of glucocorticoids. There is
no universal consensus on optimum treatment regimens. A
major issue has been the relative efficacy of daily oral versus
pulse intravenous (iv) cyclophosphamide, and comparative
toxicity of each. The Cyclophosphamide Oral versus Pulse
Trial (CYCLOPS) evaluated 149 patients with GPA or MPA
who received either oral (2 mg/kg per day; maximum oral
dose 200 mg) or iv pulse cyclophosphamide (15 mg/kg;
maximum pulse dose 1.2 g), initially every 2 weeks for the
first three pulses then every 3 weeks for the next three to six
pulses. The two treatment groups had no difference in time to
remission, renal survival, mortality, or adverse events (37,38).
Although the rate of relapse was approximately twice as
high in the iv group after long-term follow-up, there were
no differences between the groups with respect to renal
and patient outcomes. This may favor the use of iv pulses
because of the reduced cumulative dose of cyclophospha-
mide. Vigilance for leukopenia and infections is prudent
with cyclophosphamide therapy. High cumulative dose of
cyclophosphamide should be avoided by using alternative
therapies for induction of remission, maintenance of re-
mission, and treatment of relapses.
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Initial high-dose iv or oral glucocorticoid administration is
followed by tapering does of oral prednisone. The dose and
duration of prednisone therapy varies, and may be influenced
by the rate and extent of disease remission. A meta-analysis
concluded that longer courses of glucocorticoids are associated
with fewer relapses (41). Our goal is to discontinue prednisone
after 4–5 months if remission has been induced. Continuing
prednisone beyond 6months is associatedwith increased risk of
infection, and may not provide significant benefit (42).
Targeted B cell therapy to eliminate pathogenic ANCA is
conceptually attractive because this could selectively re-
duce antibody production while preserving other adaptive
and innate immune cells. Rituximab, which is an mAb that
targets CD20 on B cells, is an alternative to cyclophospha-
mide. Two controlled prospective clinical trials, Rituximab
versus Cyclophosphamide for ANCA-associated Vasculitis
(RAVE), and Rituximab versus Cyclophosphamide in ANCA-
associated Renal Vasculitis (RITUXIVAS), have demonstrated
the value of targeted B cell therapywith rituximab in induction
therapy for ANCA disease (39,40), which led to Food and
Drug Administration approval for induction therapy. In the
RITUXIVAS trial, patients in the rituximab group also
received iv cyclophosphamide, whereas in the RAVE trial,
patients in the rituximab group did not receive cyclophos-
phamide. All patients in both trials received iv and oral
glucocorticoid therapy. Patients in the RITUXIVAS trial had
more severe kidney disease. Both trials showed that ritux-
imab was noninferior for inducing remission compared with
iv cyclophosphamide (RITUXIVAS trial) or oral cyclophos-
phamide (RAVE trial). Adverse events were not reduced
in the patients treated with rituximab in either trial.
A biomarker that can guide rituximab therapy would be
valuable. Bunch et al. (43) have observed that the percent-
age of peripheral blood CD5-positive regulatory B cells is
a useful indicator of disease activity, remission, and future
relapse after rituximab therapy, and thus may help mea-
sure the effectiveness of induction therapy and guide
maintenance therapy vigilance for relapse. To our knowl-
edge, assays for CD5-positive B cells are not routinely
available in clinical laboratories, although this test could
be added to current flow cytometry lymphocyte phenotyping
assays as a locally validated laboratory-developed test.
Plasmapheresis is another strategy to remove patho-
genic ANCA, as well as inflammatory mediators, from the cir-
culation. Plasmapheresis has been shown to have a
therapeutic effect in patients with ANCA disease (includ-
ing ANCA plus anti-GBM disease) who have severe renal
impairment (serum creatinine .6 mg/dl or requiring di-
alysis), and those with alveolar hemorrhage (44,45). The
MEPEX (Methylprednisolone versus Plasma Exchange Trial)
evaluated patients with severe renal disease (serum creati-
nine .5.8 mg/dl) treated with oral cyclophosphamide and
glucocorticoids, and either plasmapheresis or pulse iv meth-
ylprednisolone (46). Plasmapheresis was associated with
increased rate of renal recovery compared with methylpred-
nisolone at both 3 and 12months of follow-up. Severe adverse
event rates and patient survival were similar in both groups.
The Plasma Exchange and Glucocorticoids for Treatment
of ANCA-Associated Vasculitis trial (PEXIVAS) is under-
way to evaluate plasma exchange in patients with GPA or
MPA with pulmonary hemorrhage and/or severe renal
disease (47). All patients will receive standard induction
therapy with cyclophosphamide or rituximab. Patients will
be randomized to receive seven plasma exchanges and
either standard or low-dose glucocorticoids, or no plasma
exchange and either standard or low-dose glucocorticoids
(47). The goal is to determine whether plasma exchange
combined with immunosuppressive therapy is effective in
Figure 5. | ANCA vasculitis treatments algorithm in accord with current practice at the University of North Carolina Kidney Center. IV, intravenous.
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reducing death and ESRD. The trial will also study whether
low-dose glucocorticoid therapy is as effective as standard
glucocorticoid therapy.
Maintenance of Remission
Once remission has been induced, continued lower-level
immune suppression is needed for most patients to prevent
relapse, which usually entails low-dose glucocorticoids
plus an additional immunomodulatory therapy such as
azathioprine, rituximab, or mycophenolate mofetil (MMF)
for 12–18 months. Patients with PR3-ANCA or GPA are
more likely to relapse than patients with MPO-ANCA,
MPA, or RLV (Table 4). Maintenance therapy may be for
a shorter interval or not required for patients at low risk
for relapse, such as patients with MPO-ANCA who have
complete remission and are MPO-ANCA negative. More
prolonged maintenance may be appropriate for patients
with increased risk for relapse, such as PR3-ANCA posi-
tivity, prior recurrence, and pulmonary involvement. Sus-
tained use of cyclophosphamide is not recommended
because of toxicity. A randomized controlled trial compar-
ing cyclophosphamide for 12 months with maintenance
therapy with azathioprine once complete remission is
attained demonstrated no difference in outcome including
relapse rate (48,49). Compared with azathioprine, mainte-
nance therapy with MMF was associated with a signifi-
cantly higher rate of relapse (50,51). Nevertheless, MMF
remains an option for maintenance therapy in patients who
are intolerant or allergic to azathioprine. Methotrexate may
be useful in maintaining remission in patients with mild
disease and no renal impairment.
Rituximab is another option for maintenance of remis-
sion. The Maintenance of Remission using Rituximab in
Systemic ANCA-associated vasculitis trial (MAINRITSAN)
compared rituximab (500 mg iv every 6 months) to aza-
thioprine for remission maintenance in patients with MPA,
RLV, and GPA in complete remission after induction treat-
ment with a cyclophosphamide and glucocorticoid reg-
imen (50). Rituximab was better than azathioprine for
preventing relapse, including renal relapse.
The optimum duration of maintenance therapy depends on
multiple factors. Ending too soon increases the risk of relapse.
Patients with PR3-ANCA (versus MPO-ANCA), lung, or
upper respiratory tract vasculitis have a higher risk for
relapse that warrants longer maintenance therapy (52,53).
However, in a randomized controlled trial of patients with
PR3-ANCAdisease who remained ANCA-positive at the time
of stable remission, extending the duration of maintenance
therapy with azathioprine from 1 year (followed by taper) to 4
years (followed by taper) was not associated with a significant
difference in relapse-free survival at 4 years (54). The result of
this study should not be extrapolated to other agents, and the
optimal duration of maintenance therapy with rituximab has
not been formally evaluated. Conversely, patients with none
of the risk factors of relapse may not need an extended
duration of maintenance therapy.
Relapse Treatment and Other Challenges
Some patients with ANCA disease are refractory to in-
duction of remission. In some studies, patients with PR3-
ANCA aremore likely to have refractory disease (53). Options
for the treatment of refractory disease include the addition of
plasmapheresis, or the addition of rituximab to a cyclophos-
phamide-based regime, or vice versa.
In patients with very severe disease at the time of diag-
nosis, such as dialysis-dependent kidney disease with
extensive glomerular scaring on renal biopsy, a decision
to treat with toxic immunosuppressive therapy can be dif-
ficult. However, patients with ANCA GN with severe
kidney failure at the initiation of therapy have a low but not
negligible response to treatment. In a study of 155 patients
with ANCA GN with eGFR,15 ml/min per 1.73 m2 at
presentation, within 4 months after biopsy, 51% attained
treatment response, 35% remained on dialysis, and 14% died
(4). However, only 5% of patients who remained on dialy-
sis after 4 months subsequently recovered renal function,
indicating that continued immunosuppressive therapy is un-
likely to benefit patients who are dialysis dependent for .4
months provided there are no extrarenal manifestations.
Throughout the treatment of ANCA disease with immu-
nosuppressive agents, the onset of adverse events must be
monitored carefully, especially infections and cancer. In a
retrospective study of 489 patients with ANCA disease
receiving standard therapies, McGregor at al. observed 1-,
2-, and 5-year cumulative incidence of infection of 51%,
58%, and 65%, and severe infection was 22%, 23%, and 26%.
Pulmonary and upper respiratory infections were most com-
mon, and Staphylococcus aureus was the pathogen identified
most often in positive cultures (41%) (42). Prophylactic therapy
that could decrease infection-associated morbidity and mor-
tality should be considered in at-risk patients.
Risk for developing cancer after treatment for MPA and
GPA was 1.6–2.4 times higher than the general population
in patients with MPA and GPA who received immuno-
suppressive therapy in the 1970s and 1980s, especially for
bladder cancer and leukemia (55). In an analysis of .500
patients with ANCA vasculitis enrolled between 1995 and 2002
in four European clinical trials, cancer rates for immunosup-
pressed patients with MPA and GPA exceeded rates for the
general population (1.58 for cancers at all sites, 1.30 for cancers
at all sites excluding nonmelanoma skin cancer), but were
less than the rates reported from earlier studies. The authors
hypothesized that the smaller risk might reflect less extensive
use of cyclophosphamide in recent treatment protocols.
Conclusion
Prompt diagnosis and rapid initiation of effective treat-
ment are the most important factors for optimum outcome
in patients with ANCA disease. Prompt diagnosis requires
an appropriate index of suspicion, familiarity with the
broad range of presenting symptoms and signs, and the
knowledge required to accurately distinguish ANCA vas-
culitis and GN from other forms of small vessel vasculitis
and GN with similar presentations. Optimum treatment
requires an understanding of the implications on treatment
regimens of different serotypes, different clinicopathologic
phenotypes, and different degrees of activity, chronicity,
and severity. Current management strategies are superior
to those in earlier decades because of more effective and
more targeted drugs, and treatment regimens that are more
personalized to the nature of the disease in individual
patients. Ongoing advances in understanding ANCA dis-
ease mechanisms, and development of more effective, less
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toxic, and more targeted therapies, undoubtedly will lead
to even better outcomes in the future.
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